dc.contributor.author |
Turan, N |
|
dc.contributor.author |
Benekli, M |
|
dc.contributor.author |
Unal, OU |
|
dc.contributor.author |
Unek, IT |
|
dc.contributor.author |
Tastekin, D |
|
dc.contributor.author |
Dane, F |
|
dc.contributor.author |
Algin, E |
|
dc.contributor.author |
Ulger, S |
|
dc.contributor.author |
Eren, T |
|
dc.contributor.author |
Topcu, TO |
|
dc.contributor.author |
Turkmen, E |
|
dc.contributor.author |
Babacan, NA |
|
dc.contributor.author |
Tufan, G |
|
dc.contributor.author |
Urakci, Z |
|
dc.contributor.author |
Ustaalioglu, BO |
|
dc.contributor.author |
Uysal, OS |
|
dc.contributor.author |
Ercelep, OB |
|
dc.contributor.author |
Taskoylu, BY |
|
dc.contributor.author |
Aksoy, A |
|
dc.contributor.author |
Canhoroz, M |
|
dc.contributor.author |
Demirci, U |
|
dc.contributor.author |
Dogan, E |
|
dc.contributor.author |
Berk, V |
|
dc.contributor.author |
Balakan, O |
|
dc.contributor.author |
Ekinci, AS |
|
dc.contributor.author |
Uysal, M |
|
dc.contributor.author |
Petekkaya, I |
|
dc.contributor.author |
Ozturk, SC |
|
dc.contributor.author |
Tonyali, O |
|
dc.contributor.author |
Cetin, B |
|
dc.contributor.author |
Aldemir, MN |
|
dc.contributor.author |
Helvaci, K |
|
dc.contributor.author |
Ozdemir, N |
|
dc.contributor.author |
Oztop, I |
|
dc.contributor.author |
Coskun, U |
|
dc.contributor.author |
Uner, A |
|
dc.contributor.author |
Ozet, A |
|
dc.contributor.author |
Buyukberber, S |
|
dc.date.accessioned |
2022-03-30T13:17:09Z |
|
dc.date.available |
2022-03-30T13:17:09Z |
|
dc.date.issued |
2015 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/59369 |
|
dc.description.abstract |
Background: We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma (PAC). |
|
dc.description.abstract |
Methods: A total of 563 patients who were curatively resected for PAC were retrospectively analyzed between 2003 and 2013. |
|
dc.description.abstract |
Results: Of 563 patients, 472 received adjuvant chemotherapy (CT) alone, chemoradiotherapy (CRT) alone, and chemoradiotherapy plus chemotherapy (CRT-CT) were analyzed. Of the 472 patients, 231 were given CRT-CT, 26 were given CRT, and 215 were given CT. The median recurrence-free survival (RFS) and overall survival (OS) were 12 and 19 months, respectively. When CT and CRT-CT groups were compared, there was no significant difference with respect to both RFS and OS, and also there was no difference in RFS and OS among CRT-CT, CT and CRT groups. To further investigate the impact of radiation on subgroups, patients were stratified according to lymph node status and resection margins. In node-positive patients, both RFS and OS were significantly longer in CRT-CT than CT. In contrast, there was no significant difference between groups when patients with node-negative disease or patients with or without positive surgical margins were considered. |
|
dc.description.abstract |
Conclusions: Addition of radiation to CT has a survival benefit in patients with node-positive disease following pancreatic resection. |
|
dc.source |
CHINESE JOURNAL OF CANCER RESEARCH |
|
dc.title |
Impact of adjuvant treatment modalities on survival outcomes in |
|
dc.title |
curatively resected pancreatic and periampullary adenocarcinoma |
|